Apparatus, systems, and methods for percutaneous pneumatic cardiac assistance

A minimally invasive cardiac assist device with a percutaneous catheter system addresses the challenges of large surgical incisions and infection risks in VADs by using a balloon effector synchronized with the cardiac cycle, offering effective ventricular support with reduced surgical trauma and infection risk.

JP2024159951AInactive Publication Date: 2024-11-08PERCASSIST INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2024148483
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2019-02-26
Filing Date
2024-08-30
Publication Date
2024-11-08
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

Current ventricular assist devices (VADs) for patients with severe heart failure require large surgical incisions, are inconvenient due to electrical power dependence, and pose infection risks through large percutaneous cords, making them difficult for patients to manage.

Method used

A minimally invasive cardiac assist device with a percutaneous catheter system that uses a balloon effector synchronized with the patient's cardiac cycle, anchored within the pericardium, and operated by an external drive unit to provide ventricular support, reducing infection risk and surgical intervention.

Benefits of technology

The system provides effective cardiac support with reduced surgical trauma and infection risk, allowing for easier replacement and disinfection, enhancing patient comfort and safety.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024159951000001_ABST
    Figure 2024159951000001_ABST
Patent Text Reader

Abstract

To provide apparatus, systems, and methods for preferable percutaneous pneumatic cardiac assistance.SOLUTION: A cardiac assist system includes a pneumatic effector which is implanted beneath a pericardial sac and over a myocardial surface overlying the patient's left ventricle. A port is implanted and receives a percutaneously introduced cannula. The port is connected to supply a driving gas received from the cannula to the pneumatic effector. An external drive unit includes a pump assembly and control circuitry which operates the pump to actuate the pneumatic effector in response to the patient's sensed heart rhythm. A connecting tube has a pump end connected to the pump and a percutaneous port-connecting end attached to the implantable port.SELECTED DRAWING: Figure 1
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] (CROSS REFERENCE TO RELATED APPLICATIONS) This application claims the benefit of U.S. Provisional No. 62 / 810,866, filed February 26, 2019 (Attorney Docket No. 56027-703.101), the entire contents of which are incorporated herein by reference.

[0002] The present invention relates generally to medical devices, systems and methods, and more particularly, to a system for providing cardiac assistance to patients suffering from late stage heart failure.

[0003] Various ventricular assist devices (VADs) have been proposed for use in supporting blood circulation in patients with severe heart failure. VADs are also used as a "bridge to transplant" to keep patients alive until a donor heart is available for transplant. In the United States, as many as 50,000 patients require a heart transplant annually due to end-stage heart failure. Donor hearts are available for only 2,000-2,500 patients per year. Many patients who cannot receive a transplant can survive by receiving a VAD.

[0004] However, placement of currently available VADs often requires a large surgical incision, typically either a sternotomy or a thoracotomy. It is difficult for patients with heart failure to undergo such a large surgical procedure. Although some minimally invasive VADs, such as intravascular rotational pumps and external compression devices, have been proposed, such minimally invasive systems typically require a large percutaneous "lifeline" to provide power to drive the implanted pump auxiliary components. Such cords are inconvenient, uncomfortable, and present a substantial risk of infection. Also, if infected, removal of the large cord often requires surgical intervention.

[0005] For these reasons, it would be desirable to provide improved devices, systems, and methods for providing cardiac assistance to patients suffering from late stage heart failure. It would be particularly desirable to provide such systems that could be implanted via subxiphoid and other established minimally invasive routes. It would further be desirable to provide VAD systems with percutaneous connectors that reduce the risk of infection and are easier to replace and disinfect if they become infected. At least some of these requirements will be met by the invention described and claimed herein. [Background technology]

[0006] Relevant patents and publications include US2019 / 0076250, US2008 / 0275295, US2007 / 0073218, US10391216, US10220128, US9259318, US8092363, US7468029, US6602182, US6432039, US6238334, US5713954, US4957477, and WO1998 / 005289. Summary of the Invention [Means for solving the problem]

[0007] The present invention provides a minimally invasive cardiac assist device for patients suffering from heart failure or other impaired cardiac function. The device typically comprises an implantable cardiac assist catheter configured to be advanced over a guidewire to a location within the patient's pericardium between the myocardial surface and the inner surface of the pericardium. The implantable cardiac assist catheter has a balloon or other pneumatic effector at its distal end, and an external drive unit is typically provided to synchronize balloon inflation with ventricular contractions of the patient's natural cardiac cycle to compress the heart and provide ventricular assist, thereby increasing the patient's cardiac output. The relative inflexibility of the fibrous pericardium provides a restrictive compression that forces the expanding balloon to compress the ventricles. In addition, the sternum also covers the heart, providing bony containment and enhancing cardiac compression in response to balloon inflation. The cardiac assist device may be used in conjunction with a sensor to obtain an electrocardiogram signal for synchronized balloon inflation.

[0008] The intrapericardial cardiac assist catheter may be anchored only at the entry point within the pericardium. Alternatively, it may enter the pericardium near the apex and exit the pericardium more superiorly toward the base, with an expansion anchor such as a small balloon near the distal tip of the catheter and outside the pericardium to maintain the position of the ventricular compression balloon. The ventricular compression balloon may be elliptical in shape with a length sized to extend along a major portion of the ventricular cavity. The ventricular compression balloon may be inflated with a fluid, either gas or liquid, usually gas, to reduce inflation / deflation time. Gas may be preferred as this allows for a quick response time for balloon inflation and deflation. The frequency of balloon inflation should be equal to the physiological heart rate, i.e., about 70 bpm. A small reservoir may be attached to the proximal end of the catheter. One surface of the reservoir may contain a septum or other elastic portion through which the needle is inserted for balloon inflation while sealing against the inserted needle. Alternatively, the entire reservoir may be constructed from an elastic material that self-seals against needle puncture. Following catheter placement, the reservoir may be implanted subcutaneously through a small skin incision, cardiac assist, and oriented with the elastic surface facing toward the skin. The balloon catheter and attached subcutaneous reservoir remain implanted while the inflation pump, controller, and battery reside external to the patient's skin, and a percutaneous needle is used to inflate and deflate the ventricular compression balloon through the implanted reservoir. This configuration facilitates pump and battery exchange while reducing the potential for catheter infection as the small diameter needle traverses the skin. The needle puncture site may also be periodically altered to reduce the potential for needle tract infection.

[0009] The ventricular compression balloon may be inflated and deflated using an external battery-operated pump that resides outside the patient's body. The pump may be bidirectional in flow with an attached fluid reservoir, or in the case of air inflation of the ventricular compression balloon, the pump inlet and outlet may be vented directly to room air. The ventricular compression balloon inflation is synchronized to the cardiac cycle using an electrical sensor that senses the patient's ECG (electrocardiogram) signal and initiates balloon inflation at the onset of the QRS complex. Patient ECG sensing may be performed via a conductive needle from an external unit that pierces the patient's skin to perform the balloon inflation. Alternatively, ECG electrodes or other sensors may be placed in the implantable port and / or catheter, and the needle may be used to provide a connection to the ECG circuitry in the external controller. A control unit in the external pump module receives the ECG signal and triggers balloon inflation during systole. Active balloon deflation is performed by the pump during diastole. Balloon inflation may also be performed using a hydraulic system that contains a pressurized fluid tank that provides balloon inflation during systole, and a pressure release valve that allows balloon deflation during diastole. The fluid tank may be periodically repressurized or the battery operated compressor may be part of a unit that resides outside the patient's body.

[0010] Although a percutaneous approach is described above, the ventricular compression balloon device may be inserted via a minimally invasive surgical approach using a small 4 cm subxiphoid incision to access and puncture the pericardial sac near the apex. A guidewire and tapered dilator may be inserted into the intrapericardial space in front of the heart at the apex site and advanced to exit the pericardial sac at a superior location on the left side of the pericardial sac. The dilator may then be removed from the patient and a ventricular compression balloon catheter may be advanced into position across the left ventricle over the guidewire for cardiac assist.

[0011] In some embodiments, the percutaneous ventricular assist device may comprise a balloon catheter inserted into the patient's pericardium near the apex of the heart via a subxiphoid puncture site. A reservoir containing an elastomeric surface is attached to the proximal end of the catheter. A 4 cm incision is made to expand the subxiphoid puncture site, and the reservoir is implanted subcutaneously in the epigastric region of the abdominal wall. In such a device, a single needle penetrates the patient's skin and the elastic surface of the reservoir, allowing a pump unit external to the patient to inflate and deflate the balloon catheter, compressing the patient's ventricle during systole. Balloon inflation is triggered by the patient's ECG as sensed in real time.

[0012] A minimum of two electrodes are required to acquire an ECG signal. In previous devices, an expanding needle formed one electrode and the second electrode consisted of a surface electrode with an adhesive patch for skin attachment on the patient's abdomen or chest. ECG signals acquired from needles inserted through body tissue are superior to ECG signals acquired from surface electrodes because the needles are less susceptible to motion artifacts and noise than surface electrodes. The proposed design incorporates one, two, or more electrodes integrated into an implantable reservoir, with a conductive mesh extending from each electrode to provide an expanded target to accommodate needle placement. The dimensions of the openings in the mesh are an interference fit with the circumference of the needle, so that upon needle insertion, the mesh applies a compressive force against the outer surface of the needle, ensuring optimal ECG signal conduction. The needle may contain a series of bulbous portions or barbs to facilitate anchoring of the target electrode in the mesh component and prevent inadvertent needle dislodgement.

[0013] The body of the reservoir may be constructed from an implantable polymeric material such as polycarbonate or polyvinyl chloride. The electrodes may be constructed from a conductive metal such as stainless steel. If a single electrode is incorporated into a reservoir, the electrode may be a metal ring attached to the outer diameter of the polymeric reservoir. If two electrodes are incorporated into a single reservoir, one electrode may be attached to the outer diameter of the reservoir and the other electrode may be a smaller diameter concentric metal ring attached to the elastomeric surface of the reservoir. A stainless steel mesh may extend radially inward from the outer electrode toward the inner electrode, with a circumferential gap between the inner edge of the mesh and the outer edge of the inner electrode to act as an insulator between the two electrodes. Alternatively, the two electrodes may be formed by two diametrically opposed arcs on the outer diameter of the reservoir, with the steel mesh extending between the two ends of each arc to preserve a non-conductive area between the two conductive mesh regions. A combination of multiple electrodes on multiple reservoirs may be applied, for example, two electrodes may be present on one implanted reservoir and a single electrode may be present on a second implanted reservoir, resulting in a three-lead EKG sensing array.

[0014] In an additional embodiment of the invention, a circuit board that receives the EKG signal and controls the activation of the external pump unit is located within the reservoir. The signal from the control board is transmitted to the external pump unit via fiber optic transmission, ensuring minimal signal noise due to patient motion. A fiber optic connection consisting of a circumferential array around one of the inflation needles mates with a corresponding circular array in the circuit board. A funnel guide is incorporated into the inner concentric electrode of the reservoir, ensuring that needle insertion results in mating of the individual fiber optic arrays on the needles and the control board within the reservoir. Two needles inserted through the mesh electrode carry the current from the external unit and power the circuit board inside the reservoir.

[0015] In a first aspect, the invention provides a cardiac assist system comprising a pneumatic effector configured to be implanted beneath a patient's pericardium and over a myocardial surface typically covering the patient's left ventricle. The system further comprises an implantable port configured to receive a percutaneously introduced cannula, which supplies a drive gas to the pneumatic effector. Typically, the pneumatic effector may be a balloon located near a distal end of a catheter or other tubular body, and the implantable port is connected to the catheter or other tube near a proximal end.

[0016] The cardiac assist system further comprises an external drive unit including a pump assembly and a control circuit. The pump assembly includes at least one pump for delivering gas, typically ambient air, to the cannula. The control circuit is typically configured to operate the pump to actuate the pneumatic effector in response to a sensed cardiac rhythm of the patient. Typically, the connecting tube has a pump end that is attachable to the pump of the pump assembly and a cannula end that is attached to the cannula.

[0017] In certain embodiments, the pneumatic effector may comprise an inflatable bladder, such as a medical balloon, typically a non-distensible medical balloon on a catheter, configured to seat across the left ventricle from the patient and beneath the inner surface of the pericardium. The balloon will typically have a volume in the range of 50 ml to 200 ml, typically 76 ml to 125 ml, when fully inflated. In other cases, the pneumatic effector may comprise some other pneumatically actuable mechanical device, such as a piston and cylinder arrangement.

[0018] In other cases and embodiments of the invention, the implantable port may include a needle-pierceable septum and a cannula comprising a needle or other sharpened tube or hollow probe configured to percutaneously penetrate the patient's tissue overlying the septum, typically the abdominal wall, and to further penetrate the septum to fluidly connect the pump assembly and external drive unit with the interior of the port so that air or other gas may be delivered under pressure to inflate or otherwise actuate the pneumatic effector.

[0019] In a specific instance, the septum will have a large enough area to provide multiple sites for needle penetration. This is particularly advantageous when the percutaneous insertion site becomes infected. By having multiple needle penetration sites, the needle may be removed from the infected area, the patient treated, and a new or sterile needle introduced into the implantable port through an alternate site on the septum. In this manner, neither the implantable port nor the pneumatic effector need to be removed or otherwise significantly disturbed in order to treat the infection.

[0020] However, in alternative embodiments, the implantable port may include a mechanical valve for eliminating needles or other cannulas. Such mechanical ports are well known for hemodialysis access and other purposes. See, e.g., U.S. Pat. No. 6,120,492, the entire disclosure of which is incorporated herein by reference.

[0021] In still further embodiments, the system of the present invention will further comprise at least one electrocardiogram (ECG) electrode arranged and configured to detect the patient's cardiac rhythm. The ECG electrodes may be located externally as in conventional ECG detection systems and may comprise one, two, three, four or more external electrodes. However, for convenience, one or more ECG electrodes may be incorporated into the cardiac assist system. For example, electrodes may be provided by or incorporated into a needle or other cannula used to access the implantable port. Alternatively or in addition, one or more ECG electrodes may be located on or coupled to the implantable port itself. For example, one, two, three, four or more ECG electrodes may be attached to the exterior surface of the port housing, the port septum or other membrane, or elsewhere on the port. Further alternatively or in addition, one or more ECG electrodes may be located on the connecting tube or on the pneumatic effector itself.

[0022] In systems with ECG electrodes, the external drive unit will typically also include an ECG circuit to detect the cardiac rhythm and synchronize operation of the pump assembly with the cardiac rhythm. When ECG electrodes are present on the implantable port or any portion of the connecting tubing, electrical conductors may be provided in or through the needle or other cannula to deliver electrical signals to the ECG circuit. When the needle or other cannula itself includes ECG electrodes, the needle or other cannula may be connected to the ECG circuit through conductors in a tube or other structure that connects the cannula to an external electrode. Conventional external ECG electrodes may be connected to an external controller by conventional ECG leads.

[0023] The control circuitry within the external drive unit will typically be configured to activate the pneumatic effector in synchrony with the patient's cardiac rhythm as measured by the ECG. For example, the control circuitry may be configured to activate the pneumatic effector at each occurrence of an R-wave peak. Often, the control circuitry will further be configured to detect an abnormal cardiac rhythm. For example, the control circuitry may compare the time between successive individual R-peaks and determine the occurrence of an abnormal cardiac rhythm based on the time increasing or decreasing above a predetermined threshold percentage, such as 300 percent, typically 250 percent. Alternatively or additionally, the control circuitry may compare the time between successive cumulative R-peaks and determine whether an abnormal cardiac rhythm is present based on the aggregate variability exceeding a predetermined threshold percentage, typically 300 percent, typically 250 percent.

[0024] When the control circuit detects an abnormal cardiac rhythm, it may take any of several actions. For example, the control circuit may simply stop actuation of the pneumatic effector until the cardiac rhythm returns to a normal pattern. Alternatively, the control circuit may actuate the pneumatic effector at a predetermined fixed rate, typically within the range of 50 beats per minute (bpm) to 80 bpm, and continue such actuation until normal cardiac rhythm is re-established. As a further alternative, the control circuit may be configured to actuate the pneumatic effector at a rate that is "proportionately" modified relative to the patient's cardiac rhythm when an abnormal cardiac rhythm is detected. That is, while actuation of the pneumatic effector would typically be at a 1:1 ratio when the cardiac rhythm is normal, the rate may be changed to another ratio when an abnormal cardiac rhythm is detected. For example, if the patient suffers from an abnormally high heart rate (tachycardia), the rate at which the pneumatic effector is triggered may be reduced. The pneumatic effector may be triggered once every two heart beats (1:2), once every three heart beats (1:2), or an equivalent frequency.

[0025] In yet a further embodiment, the pump assembly of the cardiac assist system may be configured to alternately deliver drive gas to and withdraw drive gas from the pneumatic effector. Each cycle of delivery and withdrawal would correspond to a single trigger event from the control circuitry of the external controller. The cycle of pump delivery and pump withdrawal would correspond to the patient's heart rate as detected from the ECG, with a single cycle typically lasting approximately 1 second for a patient with a heart rate of 60 bpm. It should be understood that such rapid inflation and contraction would require a fast acting system, and the available gas delivery volume, fluid communication lumen dimensions, and the like, would need to comply with the required inflation and deflation times. To achieve rapid delivery and extraction times, the delivered fluid would typically be a gas, usually ambient air.

[0026] The pump assembly may take any one of a variety of configurations for delivering and withdrawing fluid to the pneumatic effector. For example, the pump assembly may include a single pump that operates in a single flow direction and further includes the necessary valves to direct gas from the inflation direction to the contraction direction. Alternatively, the pump assembly may include a pair of pumps, one operating in the fluid delivery direction and the other operating in the fluid extraction direction. It should further be appreciated that the pump assembly may connect to any single cannula that provides both fluid delivery and fluid extraction from the implantable pump. Alternatively, the pump assembly may connect to a pair of cannulas, one for delivering inflation fluid and one for extracting inflation fluid.

[0027] In a second aspect, the present invention provides a method for assisting cardiac function in a patient suffering from heart failure. The method may include the steps of sensing the patient's ECG and determining the cardiac rhythm. An implanted port in the patient is percutaneously accessed with a cannula, and a drive gas is delivered through the cannula to the connected port and then to a pneumatic effector implanted across the patient's left ventricle. Delivery and extraction of the drive gas is synchronized with the sensed cardiac rhythm to cause the pneumatic effector to compress the heart at a rate that generally matches the patient's natural cardiac rhythm.

[0028] In certain embodiments, the pneumatic effector will be implanted beneath the patient's pericardium and across the myocardial surface. In further particular embodiments, the pneumatic effector will be on a cardiac assist catheter that enters through the pericardium at an entry location and, in some cases, has a distal tip that passes out through the pericardium at an exit location. An anchor, such as a small tethered balloon, may be provided on the distal tip of the cardiac assist catheter to stabilize the pneumatic effector at a desired location within the pericardium.

[0029] In still further specific embodiments, the ECG may be detected in various ways. For example, one or more ECG electrodes may be located on the implanted port, on the implanted pneumatic effector, or elsewhere on the implanted portion of the system. In such cases, signals from the implanted ECG electrodes may be delivered to an ECG circuit in the external controller using a cannula as a percutaneous transmission element or conductor. In other specific embodiments, the cannula or cannulas themselves may act as ECG electrodes after they are introduced percutaneously into the implanted port. In still other specific embodiments, the ECG signal may be measured by one or more external electrodes attached to the patient in a conventional manner. It should be understood that a single channel ECG may be used, but preferably at least a two-channel ECG, preferably a three-channel ECG, a four-channel ECG, or more would be employed. Electrodes may also be placed on the implanted pneumatic effector to provide cardiac pacing in the event of bradycardia in the patient, or cardiac defibrillation in the event of ventricular tachycardia, ventricular fibrillation, or cardiac arrest in the patient.

[0030] The method of the present invention further optionally includes a step of detecting an abnormal cardiac rhythm. The abnormal cardiac rhythm is determined based on the measured ECG, and the presence of the abnormal cardiac rhythm will typically result in a step of stopping or modifying the operation of the pneumatic effector. For example, the drive gas may be stopped when the abnormal cardiac rhythm is detected. Alternatively, the delivery rate of the drive gas may be altered when the abnormal cardiac rhythm is detected. In particular, the drive rate may be reduced in the presence of a rapid heart rate (tachycardia) or increased in the presence of a slow heart rate (bradycardia).

[0031] The methods of the present invention further include protocols for treating the patient if the tissue access site becomes infected. In such cases, the needle or other cannula is removed from the tissue tract, the tissue tract is treated for infection, and the cannula (either disinfected or a new cannula) may be reintroduced into the implanted port, typically through a different access route. For example, for a septum-type port, the cannula may be introduced into a different region of the portion through a new tissue tract in uninfected tissue.

[0032] In a third aspect, the present invention provides an implantable cardiac assist catheter for use with an external drive unit, the implantable cardiac assist catheter comprising a catheter body having a proximal and distal end. A pneumatic effector is attached to the distal end of the catheter body and configured to be implanted beneath the patient's pericardium and over a myocardial surface covering the patient's left ventricle. An implantable port is attached to the proximal end of the catheter body and configured to receive a percutaneously introduced cannula. The port is connected to supply drive gas received from the cannula through a gas lumen in the catheter body to the pneumatic effector. By controlling the supply of drive gas to the implantable port, the pneumatic effector can be driven at a desired rate as controlled by the external drive unit.

[0033] In certain embodiments, the implantable cardiac assist catheter may include a distal tip having a guidewire lumen with an entry port and an exit port, both ports being located distal to the pneumatic effector. Such a "monorail" construction is advantageous because it allows the remainder of the catheter body to have only a single fluid delivery lumen, thus reducing the required diameter of the catheter. Thus, the gas lumen and the catheter body will typically be the only lumens present between the proximal end of the catheter body and the pneumatic effector.

[0034] Optionally, the distal tip of the implantable cardiac assist catheter may further comprise an anchoring balloon or other anchoring structure. Such an anchoring structure may be used by advancing the distal catheter tip outwardly through the pericardium. After the pneumatic effector is properly positioned, typically over the patient's left ventricle, an anchor may be deployed (e.g., by balloon inflation) to stabilize the catheter position for subsequent use.

[0035] In a fourth aspect, the invention provides an external drive unit for use with an implantable cardiac assist catheter, such as the cardiac assist catheter thus described. The external drive unit comprises a pump assembly and a control circuit. The control circuit is typically configured to operate the pump assembly to actuate a pneumatic effector on the implantable cardiac assist catheter in response to a sensed cardiac rhythm of the patient.

[0036] In certain embodiments, the external drive unit may further comprise a connecting tube having a pump end connected to the pump assembly and a percutaneous port connection end configured to be removably attached to an implantable port fluidly connected to a pneumatic effector on the implantable cardiac assist catheter. In still further embodiments, the external drive unit may include an ECG circuit configured to receive signals from at least one ECG electrode, located in any of the locations described above, the at least one ECG electrode being implanted to detect the patient's cardiac rhythm. Typically, the connecting tube will comprise at least one conductor electrically coupled to the cannula and configured to connect the ECG electrode to the ECG circuit in the external drive unit.

[0037] In still further exemplary embodiments, the control circuitry of the external drive unit may be configured to actuate the pneumatic effector in synchronization with the patient's cardiac rhythm as measured by the ECG electrodes. Actuation may generally be accomplished by detecting the occurrence of an R-wave peak, as described above. The control circuitry may be further configured to detect an abnormal cardiac rhythm and still further to stop or modify actuation of the pneumatic effector in any of the manners described above. The pump assembly may also have any of the configurations described above with respect to the cardiac assist system of the present invention.

[0038] For a more complete understanding of the nature and advantages of the present invention, reference should be made to the subsequent detailed description and the accompanying drawings. The present invention provides, for example, the following: (Item 1) 1. A cardiac assist system comprising: a pneumatic effector configured to be implanted beneath the patient's pericardium and over a myocardial surface covering a left ventricle of the patient; and an implantable port configured to receive a percutaneously introduced cannula, said port being connected to supply a drive gas received from said cannula to said pneumatic effector; 1. An external drive unit, comprising: (a) a pump assembly; (b) a control circuit configured to operate the pump to actuate the pneumatic effector in response to a sensed cardiac rhythm of the patient; and an external drive unit including: a connecting tube having a pump end attachable to the pump assembly and a cannula end attachable to the cannula; A cardiac assist system comprising: (Item 2) 2. The cardiac assist system of claim 1, wherein the pneumatic effector comprises an inflatable bladder. (Item 3) Item 1 , the cardiac assist system comprising: a piston; (Item 4) 2. The cardiac assist system of claim 1, wherein the implantable port comprises a needle-pierceable septum and the cannula comprises a needle configured to percutaneously pierce the septum. (Item 5) 5. The cardiac assist system of claim 4, wherein the septum has an area large enough to provide multiple sites for needle penetration. (Item 6) 2. The cardiac assist system of claim 1, wherein the implantable port comprises a mechanical valve for receiving the cannula. (Item 7) 2. The cardiac assist system of claim 1, further comprising at least one ECG electrode positioned and configured to detect the patient's cardiac rhythm. (Item 8) 8. The cardiac assist system of claim 7, wherein the at least one ECG electrode forms at least a part of the cannula. (Item 9) 8. The cardiac assist system of claim 7, wherein the at least one ECG electrode is located on the implantable port. (Item 10) 8. The cardiac assist system of claim 7, wherein the at least one ECG electrode is located on the connecting tube. (Item 11) 8. The cardiac assist system of claim 7, wherein the at least one ECG electrode is located on the pneumatic effector. (Item 12) 8. The cardiac assist system of claim 7, further comprising an ECG circuit within the external drive unit. (Item 13) 13. The cardiac assist system of claim 12, wherein the at least one ECG electrode connects to the ECG circuit through a conductor disposed through the connecting tube. (Item 14) 13. The cardiac assist system of claim 12, wherein the at least one ECG electrode is configured for external attachment to the patient and connected to the ECG circuit by an external lead. (Item 15) 13. The cardiac assist system of claim 12, wherein the control circuitry is configured to actuate the pneumatic effector in synchronization with the patient's cardiac rhythm as measured by the ECG. (Item 16) Item 16. The cardiac assist system of item 15, wherein the control circuit is configured to actuate the pneumatic effector upon the occurrence of an R wave peak. (Item 17) Item 16. The cardiac assist system of item 15, wherein the control circuitry is further configured to detect an abnormal cardiac rhythm. (Item 18) 20. The cardiac assist system of claim 17, wherein the control circuitry compares the time between successive individual R-peaks and determines that the abnormal cardiac rhythm is abnormal if the time increases or decreases by more than a predetermined threshold percentage. (Item 19) 20. The cardiac assist system of claim 17, wherein the control circuit compares the time between successive cumulative R-peaks and determines that the abnormal cardiac rhythm is abnormal if the aggregate variability exceeds a predetermined threshold percentage. (Item 20) 20. The cardiac assist system of claim 17, wherein the control circuitry is further configured to disable actuation of the pneumatic effector if an abnormal cardiac rhythm is detected. (Item 21) 20. The cardiac assist system of claim 17, wherein the control circuitry is further configured to actuate the pneumatic effector at a predetermined rate that is not synchronized with the cardiac rhythm when an abnormal cardiac rhythm is detected. (Item 22) 20. The cardiac assist system of claim 17, wherein the control circuitry is further configured to actuate the pneumatic effector at a rate proportionally corrected to the patient's cardiac rhythm when an abnormal cardiac rhythm is detected. (Item 23) 23. The cardiac assist system of claim 22, wherein the control circuitry is further configured to actuate the pneumatic effector at a reduced rate relative to the patient's cardiac rhythm when a tachycardia is detected. (Item 24) 2. The cardiac assist system of claim 1, wherein the pump assembly is configured to alternately deliver the drive gas to the pneumatic effector and remove the drive gas from the pneumatic effector. (Item 25) 25. The cardiac assist system of claim 24, wherein the pump assembly includes a pump connected to a valve, the pump configured to flow a drive gas in one direction, and the valve configured to alternately deliver the drive gas to and remove the drive gas from the pneumatic effector. (Item 26) 25. The cardiac assist system of claim 24, wherein the pump assembly comprises a first pump for delivering drive gas to the pneumatic drive device and a second pump for removing drive gas from the pneumatic drive device. (Item 27) 1. A method for supporting cardiac function in a patient suffering from heart failure, the method comprising: detecting an ECG of the patient and determining a cardiac rhythm; percutaneously accessing the implanted port with a cannula; delivering a drive gas through the cannula to an implanted port connected to a pneumatic effector implanted across the patient's left ventricle; Including, The method, wherein the drive gas delivery is synchronized with the determined cardiac rhythm to cause the pneumatic effector to compress the heart at a rate that matches the cardiac rhythm. (Item 28) 28. The method of claim 27, wherein the pneumatic effector is implanted beneath the patient's pericardium and over the myocardial surface. (Item 29) 28. The method of claim 27, wherein the ECG is detected using one or more electrodes located on the implanted pneumatic port. (Item 30) 28. The method of claim 27, wherein the ECG is detected using one or more electrodes located on the implanted pneumatic effector. (Item 31) 28. The method of claim 27, wherein the ECG is detected with the cannula acting as an ECG electrode. (Item 32) 28. The method of claim 27, wherein the ECG is detected using external electrodes. (Item 33) 28. The method of claim 27, further comprising detecting an abnormal cardiac rhythm. (Item 34) 34. The method of claim 33, wherein delivery of the drive gas is stopped when an abnormal cardiac rhythm is detected. (Item 35) 34. The method of claim 33, wherein the rate of delivering the drive gas is altered when an abnormal cardiac rhythm is detected. (Item 36) 36. The method of claim 35, wherein the rate is below the rate of the detected cardiac rhythm. (Item 37) Item 37. The method of item 36, wherein the rate is a predetermined fixed rate. (Item 38) 28. The method of claim 27, further comprising removing the cannula from the access site when infection of the access site is observed. (Item 39) 40. The method of claim 38, further comprising treating the infection and replacing the cannula in the implanted port. (Item 40) 40. The method of claim 39, wherein the cannula is exchanged through a different site rather than entering the port through a different location. (Item 41) Item 41. The method of item 40, wherein the cannula comprises a needle, the port comprises a needle-pierceable septum, and the different locations are different areas on the septum. (Item 42) 1. An implantable cardiac assist catheter for use with an external drive unit, said implantable cardiac assist catheter comprising: a catheter body having a proximal end and a distal end; a pneumatic effector at a distal end of the catheter body, the pneumatic effector configured to be implanted beneath the patient's pericardium and over a myocardial surface covering the patient's left ventricle; an implantable port at a proximal end of the catheter, the implantable port configured to receive a percutaneously introduced cannula, the port being connected to supply a drive gas received from the cannula through a gas lumen in the catheter body to the pneumatic effector; An implantable cardiac assist catheter comprising: (Item 43) 43. The implantable cardiac assist catheter of claim 42, wherein the catheter body comprises a distal tip having a guidewire lumen with an entry port and an exit port, both ports located distal to the pneumatic effector. (Item 44) 44. The implantable cardiac assist catheter of claim 43, wherein the gas lumen is the only lumen within the catheter body between the proximal end and the pneumatic effector. (Item 45) 43. The implantable cardiac assist catheter of claim 42, further comprising an anchor positioned on the catheter body distal to the pneumatic effector. (Item 46) 1. An external drive unit for use with an implantable cardiac assist catheter, the external drive unit comprising: (a) a pump assembly; (b) a control circuit configured to operate the pump assembly to actuate a pneumatic effector on the implantable cardiac assist catheter in response to a sensed cardiac rhythm of the patient; and An external drive unit comprising: (Item 47) Item 47. The external drive unit of item 46, further comprising a connecting tube having a pump end connected to the pump assembly and a percutaneous port connection end configured to be removably attached to an implantable port fluidly connected to the pneumatic effector on the implantable cardiac assist catheter. (Item 48) Item 48. The external drive unit of item 47, further comprising an ECG circuit within the external drive unit, the ECG circuit configured to receive signals from at least one ECG electrode, the at least one ECG electrode positioned and configured to detect a cardiac rhythm of the patient. (Item 49) Item 49. The external drive unit of item 48, wherein the connection tube comprises at least one conductor configured to removably connect to the implantable port that is electrically coupled to one or more ECG electrodes. (Item 50) Item 47. The external drive unit of item 46, wherein the control circuitry is configured to actuate the pneumatic effector in synchronization with the patient's cardiac rhythm as measured by ECG electrodes. (Item 51) Item 51. The external drive unit of item 50, wherein the control circuit is configured to actuate the pneumatic effector upon the occurrence of an R wave peak. (Item 52) Item 51. The external drive unit of item 50, wherein the control circuitry is further configured to detect abnormal cardiac rhythms. (Item 53) Item 53. The external drive unit of item 52, wherein the control circuitry is further configured to disable actuation of the pneumatic effector if an abnormal cardiac rhythm is detected. (Item 54) Item 54. The external drive unit of item 53, wherein the control circuitry is further configured to actuate the pneumatic effector at a predetermined rate that is not synchronized with the cardiac rhythm when an abnormal cardiac rhythm is detected. (Item 55) Item 54. The external drive unit of item 53, wherein the control circuitry is further configured to actuate the pneumatic effector at a rate proportionally corrected to the patient's cardiac rhythm when an abnormal cardiac rhythm is detected. (Item 56) Item 56. The external drive unit of item 55, wherein the control circuitry is further configured to actuate the pneumatic effector at a reduced rate relative to the patient's cardiac rhythm when a tachycardia is detected. (Item 57) Item 47. The external drive unit of item 46, wherein the pump assembly is configured to alternately deliver the drive gas to and remove the drive gas from the pneumatic effector. (Item 58) Item 58. The external drive unit of item 57, wherein the pump assembly includes one pump connected to a valve, the pump configured to flow drive gas in one direction, and the valve configured to alternately deliver the drive gas to and remove the drive gas from the pneumatic effector. (Item 59) Item 58. The external drive unit of item 57, wherein the pump assembly comprises a first pump for delivering drive gas to the pneumatic drive device and a second pump for removing drive gas from the pneumatic drive device. [Brief description of the drawings]

[0039] In order to better understand the invention and to see how it may be carried out in practice, certain preferred embodiments will now be described, by way of non-limiting example only, with reference to the accompanying drawings in which like reference characters represent corresponding features consistently throughout like embodiments in the accompanying drawings, in which:

[0040] [Figure 1] FIG. 1 is a perspective view of a cardiac assist system constructed in accordance with the principles of the present invention.

[0041] [Figure 2A] 2A-2D illustrate different configurations of pump assemblies suitable for use with the cardiac assist system of the present invention. [Figure 2B] 2A-2D illustrate different configurations of pump assemblies suitable for use with the cardiac assist system of the present invention. [Figure 2C] 2A-2D illustrate different configurations of pump assemblies suitable for use with the cardiac assist system of the present invention. [Figure 2D] 2A-2D illustrate different configurations of pump assemblies suitable for use with the cardiac assist system of the present invention.

[0042] [Diagram 3] 3A-3B illustrate a first implantable port configuration constructed in accordance with the principles of the present invention.

[0043] [Figure 4] 4A-4B illustrate a second implantable port embodiment constructed in accordance with the principles of the present invention.

[0044] [Diagram 5] 5A-5B illustrate a third implantable port configuration constructed in accordance with the principles of the present invention.

[0045] [Figure 6] FIG. 6 illustrates details of how a needle or other cannula engages the conductive wires of a conductive mesh that is embedded within the septum of the implantable port.

[0046] [Figure 7A] FIG. 7A illustrates a needle cannula having a retaining bulb along its length.

[0047] [Figure 7B] FIG. 7B illustrates a needle or other cannula according to the present invention having retaining barbs along its length.

[0048] [Figure 8] 8A-8B illustrate an alternative access cannula constructed in accordance with the principles of the present invention and having a fiber optic component for delivering cardiac rhythm information from an implantable port to an external drive unit.

[0049] [Figure 9] FIG. 9 illustrates an implantable port suitable for use with the access cannula of FIGS. 8A and 8B.

[0050] [Figure 10A] FIG. 10A illustrates the cardiac assist system of FIG. 1 implanted within a patient.

[0051] [Figure 10B] FIG. 10B illustrates an alternative embodiment of a cardiac assist catheter having a balloon anchor at its distal tip.

[0052] [Figure 11] FIG. 11 is a logic flow diagram illustrating the operation of the external drive unit of the cardiac assist system of the present invention. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0053] In the following description, various embodiments of the present invention will be described. For purposes of explanation, specific configurations and details are set forth to provide a thorough understanding of the embodiments. However, it will also be apparent to those skilled in the art that the present invention may be practiced without the specific details. Furthermore, well-known features may be omitted or simplified so as not to obscure the embodiments being described.

[0054] 1, a cardiac assist system 10, constructed in accordance with the principles of the present invention, may include a cardiac assist catheter 12 and an external drive unit 14. The cardiac assist catheter 12 typically includes a catheter body 18 having a balloon 20 or other pneumatic effector located at its distal end. An implantable port 24 is connected at the proximal end of the catheter body 18, and the body typically has a distal tip 26 with a short "monorail" guidewire lumen defined between a guidewire lumen entry port 28 and a guidewire lumen exit port 30. The length of the guidewire lumen will typically be between 0.5 cm and 3 cm, and typically between 1 cm and 2 cm.

[0055] The port 24 comprises a port body 38 or other enclosure having an opening on its upper surface. The opening is typically covered by a needle-pierceable septum 40.

[0056] The external drive unit 14 includes a needle 44 or other cannula attached to the distal end of a connecting tube 46. The connecting tube is attached to a pump 52 in a console 48, which further includes control circuitry 54 for controlling the pump and other operation of the cardiac assist system 10. Optionally, the external drive unit 14 may further include ECG pads 56, which are connected to the control circuitry 54 by a connecting cable 58. Typically, the pump, control circuitry, and all other active components are battery operated, and the external drive unit 14 will include a replaceable and / or rechargeable battery.

[0057] 2A-2D, the pump assembly 52 may have a variety of configurations. For example, as shown in FIG. 2A, a pump unit 52A, typically a diaphragm-type pump, includes a series of valves 60. a -60 d The pump 50A is connected to the cannula 44 by a valve 60. The pump 50A is configured to run in a single direction at all times, i.e., the inlet will always receive gas and the outlet will always deliver gas. To deliver gas to the cannula 44, the valve 60a The ambient air will flow through the pump 50A via the open valve 60. b When gas is delivered to the cannula, valve 60 c and 60 d Gas will continue to be delivered until pneumatic effector 20 is inflated, at which point valve 60 will be closed. a -60 d That is, the gas inlet valve 60 a The exhaust valve 60c is closed, the return bypass valve 60c is opened, and gas is extracted through the cannula 44 and pump 52A opens the exhaust valve 60b. d 2. Valve 60 a -60 d By reversing the open / closed status of pump 52A, the pump can be made to first deliver gas through the cannula and then extract gas through the cannula without reversing the operation of pump 52A.

[0058] As also shown in FIG. 2A, an ECG lead line 70 may be provided between the cannula 44 and the control circuitry 54 of the external drive unit 14 .

[0059] 2D, a single pump 52B may be used in conjunction with the pair of cannulas 44a and 44b. a -62 d may be used to reverse the gas flow between the cannulas. In particular, valve 62 a and valve 62 d By opening the gas delivery cannula 44, ambient air can enter the gas delivery cannula 44. a The valve 62 may then a and 62 b and close valve 62. c and 62 d By opening the exhaust valve 62, gas is allowed to flow through the cannula 44b. dThe inflow and outflow of gas may be cycled by reversing the status of the valve in a manner similar to the valve of FIG.

[0060] In FIG. 2B, each cannula 44 a and 44 b has a separate ECG lead 72 a and 72 b that is connected to the control circuitry 54 of the external drive unit 14 .

[0061] 2C, a pump assembly 52 will be described that includes two pumps 52c1 and 52c2. A control circuit 54 operates the first pump 52c1 and the valve 64. a 44, while return valve 64b remains closed. After the pneumatic effector is fully inflated or otherwise actuated, valve 64a will be closed and the pump will typically be stopped. Return valve 64b will then be actuated and pump 52c2 will be actuated to exhaust gases through cannula 44 and out through the exhaust line, as shown. The operation of the two pumps and valves may be reversed periodically to cycle the delivery and exhaust gases to and from the implanted port at a desired rate.

[0062] As also shown in FIG. 2C, an ECG lead line 74 may be provided between the cannula 44 and the control circuitry 54 of the external drive unit 14 .

[0063] 2D, a fourth pump assembly configuration will be described. The assembly comprises two pumps 52d1 and 52d2. Each pump, in turn, is connected to a single cannula 44a and 44b, respectively. Valves would typically be provided, but no valves are theoretically necessary to cycle the system between gas delivery through pump 52d1 and cannula 44a and gas extraction through cannula 44b and pump 52d2; this can be accomplished simply by alternately starting and stopping the pumps during a cycle.

[0064] Also shown in FIG. 2D, each cannula 44a and 44b is connected to control circuitry 54 by an ECG lead 76a and 76b, respectively.

[0065] 3A and 3B, a first implantable port embodiment 24a is illustrated. FIG. 3A is a top view of the port with the top surface typically oriented "frontward" toward the patient's skin after it has been implanted. A ring electrode 80 is attached to the outer circumference of the implantable port 24a and may optionally act as an ECG electrode. A circumferential band of metal mesh 82 may be positioned around the outer periphery of the upper surface of the port, typically around a needle-penetrable septum 84. A second, smaller, inner ring electrode 86 may also be provided on the upper surface of the septum. The outer mesh electrode 82 is electrically insulated from the inner electrode 86 by the non-conductive septum material. Thus, first and second metal cannulas may be introduced through the inner and outer electrodes to provide separate connections for two-lead EKG signal detection. The ECG electrode itself may be located on the body of the port 44a or elsewhere within the implantable system. Internal conductive wiring may be provided between the ECG electrodes and the mesh electrodes 82 and 86 .

[0066] 4A and 4B, an alternative implantable port 24b is illustrated having first and second arcuate mesh electrodes 90a and 90b formed on an upper surface of a needle-penetrable septum 92. As shown in FIG 4B, a first electrode 94a may be positioned on the outer periphery of the port body with an internal connection to one of the two arcuate mesh electrodes. A second electrode (not shown in FIG 4B) may be located on the opposing side of the port body and connected to the other of the arcuate mesh electrodes to provide a separate cannula connection to each of the ECG electrodes.

[0067] Yet a further implantable port assembly 95 is illustrated in Figures 5A and 5B. The port assembly 95 includes a first port 24b, which may be the same as that described above with respect to Figures 4A and 4B. A second port 24c may have a single mesh electrode covering the entire surface of the underlying needle-penetrable septum. The mesh electrode 96 may be connected to any ECG electrode, typically to a conductive portion of the port body. The ports 24b and 24c are connected together through catheter portions 18a and 18b to a common catheter body 18 through a y-connector 100, which may be connected to a pneumatic effector as described above with respect to Figure 1.

[0068] 6 illustrates how the cannula 14 forms an electrical connection with the wires of the mesh electrode. In particular, the mesh electrode comprises orthogonally arranged conductive wires 102a and 102b. Small square cells are formed where the wires 102a and 102b cross. The dimensions of the cells are chosen so that they are smaller than the diameter of the cannula, and thus, when inserted through the wire mesh, the walls of the cannula 14 will necessarily contact all four wires that define a single cell. In this way, good electrical contact is ensured.

[0069] 7A, cannulas may be modified to enhance retention when they are inserted through a septum of an implantable port, and particularly through a wire mesh electrode structure on such a septum. In particular, as shown in FIG. 7A, needle structure 106 may have a series of bulbous portions 108 that help resist accidental withdrawal of the needle from the mesh. Similarly, as shown in FIG. 7B, needle 110 may have a series of barbs 112 that resist needle withdrawal.

[0070] 8A, 8B, and 9, an optical system for delivering ECG information from an implantable port to an external drive unit will be described. As shown in FIG. 8A, a needle assembly 120 comprises a needle 122 having a plurality of optical fibers 126 axially embedded within a sheath 128. As shown in FIG. 8B, the optical fibers 126 are exposed at a distal surface of the sheath 128. As shown in FIG. 9, an implantable port 130 may be modified to receive the needle assembly 120 in a manner that transmits optical information to the optical fibers 126. In particular, the needle assembly 120 may be inserted through a septum 132 of the port. An outer surface of the sheath 128 engages a niche wire embedded within the septum 132. A distal surface of the sheath 128 engages an upper surface of a circuit board 140. The circuit board 140 comprises a plurality of optical emitters (not shown) configured to deliver light to the optical fibers 126 of the needle assembly 120. The needle 122 will pass through a hole or opening 142 in the circuit board, allowing a face of the sheath to engage the circuit board. A funnel 144 is provided to aid in proper alignment of the needle with the opening. ECG electrodes 146a and 146b on the exterior of the port 130 are connected to the circuit board 140. Circuitry on the circuit board extracts the ECG information from the electrodes and converts the information to optical energy, which is delivered by an optical emitter to the optical fiber 126. The light is transmitted by the optical fiber to an external drive unit where it is converted back to electronic information suitable for controlling the system as described above.

[0071] Referring now to FIG. 10, the cardiac assist system 10 of FIG. 1 may be implanted within a patient as shown. In particular, a balloon or other pneumatic effector 20 is introduced into the pericardium between the inner surface of the pericardium P and the outer surface of the myocardium M. The pneumatic effector 20 would preferably be located generally across the left ventricle such that inflation or other actuation of the effector compresses the left ventricle, as shown by the dashed line in FIG. 10. A port 24 is connected to the balloon by a catheter body 18 and is accessed percutaneously by a cannula 14. An external drive unit 48 typically delivers an actuation gas through a connecting tube 46 as well as the cannula 14 to the port 24 to actuate the pneumatic effector by inflating and deflating the balloon. An ECG is measured by ECG pads 56, which are connected to the external drive unit by a cable 58. Optionally, other ECG signals may be measured by electrodes on the implantable port 24 or elsewhere in the system.

[0072] Referring now to FIG. 11, an exemplary protocol for operating a pneumatic effector of the present invention will be described. The patient's ECG is measured using any of the ECG electrodes described above. The ECG measurement circuitry is typically incorporated into an external drive unit and operates on well-known ECG measurement principles. The raw ECG signal undergoes processing, typically digital processing to remove motion artifacts from the signal, and the processed signal is then scanned to determine the occurrence of signal artifacts associated with the patient's heart rhythm, typically by measuring the R-peak.

[0073] Although the R-peaks may be used to directly drive pump assemblies and pneumatic effectors, typically the R-peak pattern will be evaluated to determine whether it is normal or abnormal. For example, the occurrence of successive single peak R values ​​may be compared to determine whether they are increasing or decreasing in length. If the RR peak interval remains constant within ±10 percent of the previous interval, the cardiac rhythm is deemed normal and a trigger may be generated. Often a second abnormality test will be applied to the RR interval over a cumulative number of beats, e.g., 10 beats. If the RR interval is greater than a threshold amount, e.g., 10 percent, of the average RR interval of the preceding 10 heart beats, the cardiac rhythm is deemed abnormal.

[0074] In the event that an abnormal cardiac rhythm is detected, the system may take any one of several actions. For example, the system may suspend triggering of the pneumatic effector until the patient's intrinsic cardiac rhythm returns to normal. Alternatively, in the event of a rapid heartbeat, the 1:1 synchronization between the natural cardiac rhythm and the triggering of the pneumatic effector may be modified, for example, the effector may be triggered every second natural cardiac beat (2:1 ratio), every third cardiac beat (3:1 ratio), or an equivalent ratio. Operation of the pneumatic effector at the 1:1 ratio may be resumed as soon as the cardiac rhythm returns to normal.

[0075] Although specific embodiments of the present invention have been described in detail above, it should be understood that this description is merely for illustrative purposes and that the above description of the present invention is not exhaustive. Although specific features of the present invention are shown in some drawings and not in others, this is for convenience only and any feature may be combined with another in accordance with the present invention. Several modifications and alternatives will be apparent to those skilled in the art. Such alternatives and modifications are intended to be included within the scope of the claims. Particular features presented in the dependent claims can be combined and fall within the scope of the present invention. The present invention also encompasses embodiments in which the dependent claims are written in a multiple dependent claim format with reference to other independent claims as alternatives.

[0076] The use of the terms "a" and "an" and "the" and similar referents in the context of describing the present invention (particularly in the context of the claims below) shall be interpreted to cover both the singular and the plural, unless otherwise indicated herein or clearly contradicted by context. The terms "comprising", "having", "including", and "containing" shall be interpreted as open-ended terms (i.e., meaning "including, but not limited to"), unless otherwise noted. The term "connected" shall be interpreted as contained within, attached to, or joined together, either partially or wholly, even if there is something intervening. The recitation of ranges of values ​​herein is intended merely to serve as a shorthand notation for individually referring to each separate value falling within the range, unless otherwise indicated herein, and each separate value is incorporated herein as if it were individually recited herein. All methods described herein can be performed in any suitable order, unless otherwise indicated herein or clearly contradicted by context. The use of any and all examples or exemplary language (e.g., "etc.") provided herein is intended merely to better elucidate embodiments of the invention and does not pose a limitation on the scope of the invention unless otherwise claimed. No language in the specification should be construed as indicating any non-claimed element as essential to the practice of the invention.

[0077] All references cited in this specification, including publications, patent applications, and patents, are herein incorporated by reference to the same extent as if each reference was individually and specifically indicated to be incorporated by reference and was set forth in its entirety herein.

Claims

[Claim 1] The invention described in this specification.